$195.85
+0.50%Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.
Chief Executive Officer & Director
Compensation
$5,544,754
Chief Executive Officer of GMPD segment
Compensation
$1,387,127
Chief Executive Officer of Medical Segment
Compensation
$1,362,141
Chief Executive Officer of Pharmaceutical & Specialty Solutions Segment
Compensation
$1,736,640
Chief Financial Officer
Compensation
$2,232,222
Chief Human Resources Officer
Chief Legal & Compliance Officer
Compensation
$1,722,409
Executive Vice President of Biopharma Solutions & Strategic Sourcing
Senior Vice President
Compensation
$451,344
Senior Vice President & Chief Accounting Officer
Vice President of Investor Relations
During the last 12 months, insiders have sold $13.72M worth of CAH shares, with no buying activity reported.
0
0.00
0
0.00
+0
+$0
0
0.00
6.4K
1.47M
-1.5M
-$1.47M
0
0.00
0
0.00
+0
+$0
0
0.00
81.7K
12.25M
-12.3M
-$12.25M
No buying activity
Hollar Jason M.
Officer: Chief Executive Officer
$4.40M
Weitzman Deborah
Officer: Ceo, Pss Segment
$3.22M
Alt Aaron E
Officer: Chief Financial Officer
$2.58M
Scherer Mary C.
Officer: Chief Accounting Officer
$1.01M
Hall Patricia Hemingway
Director
$919K
Strong bearish signal with $13.72M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
CAH - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | September 16, 2025 | November 05, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | September 16, 2024 | November 06, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | September 27, 2023 | November 15, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | September 28, 2022 | November 09, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | September 23, 2021 | November 05, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | September 23, 2020 | November 04, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | September 20, 2019 | November 06, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | September 26, 2018 | September 26, 2018 | 2018 | |
DEF 14A DEF 14A 2017 N/A | September 21, 2017 | November 08, 2017 | 2017 | |
DEF 14A DEF 14A 2016 N/A | September 16, 2016 | November 03, 2016 | 2016 |
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.